Michael Oleksiw says loneliness and behavior gaps drive prescription drop-offs, making early, personalized support critical to adherence.
Michael Oleksiw
Advertisement
Michael Oleksiw is the CEO of Pleio Inc.
Articles by Michael Oleksiw
Pleio CEO Michael Oleksiw discusses how loneliness can affect GLP-1 patient adherence.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Cencora-Kite Agreement Signals CGT Commercialization Shift
2
Wegovy Pill's UAE Debut Is a Distribution Story, Not Just a Market Entry
3
Q&A: Dr. Reddy's CEO on Generic Semaglutide and the GLP-1 Market Ahead
4
Q&A: Why Pharma Needs to Rethink Its Path to the Patient
5